Tian Zhang, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Grants

Publications

Bu, Jiyoon, Michael J. Poellmann, Marco Reyes-Martinez, Andrew Armstrong, Daniel George, Tian Zhang, Andrew Z. Wang, and seungpyo hong. “Abstract 6439: CapioCyte™ technology for efficient capture and downstream analysis of circulating tumor cells from renal cell carcinoma.” In Clinical Trials. American Association for Cancer Research, 2020. https://doi.org/10.1158/1538-7445.am2020-6439.

Full Text

Zhang, Tian, and Andrew Armstrong. “CLINICAL TRIALS IN PROGRESS.” Oncology New York 34, no. 8 (August 2020): 304–304.

Scholars@Duke

Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.

PMID
32923131
Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID
32253061
Full Text

Brown, Landon Carter, Ramy Sedhom, Eric B. Schwartz, Jason Zhu, Chester Kao, Matthew D. Tucker, Matthew Labriola, et al. “Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Battle, Dena, Cristiane Decat Bergerot, Pavlos Msaouel, Eric Jonasch, Tian Zhang, Daniel J. George, and Michael D. Staehler. “Patient preferences and expectations of systemic therapy in renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Garmezy, Benjamin, Tian Zhang, Andrew Leonard Laccetti, Minas P. Economides, Amishi Yogesh Shah, Nizar M. Tannir, Eric Jonasch, et al. “Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Zhang, Tian, Karla V. Ballman, Atish Dipankar Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen, Ardaman Shergill, et al. “PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Campbell, Matthew T., Tian Zhang, Lynda Chin, Allison Betof Warner, and Matthen Mathew. “ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).” In Journal of Clinical Oncology, Vol. 38, 2020.

Scholars@Duke

Pages